Identification, optimization and use of cryptic HLA-A24 epitopes for immunotherapy
The present invention discloses peptides such as an isolated peptide consisting of an immunogenic HLA-A*2402-restricted epitope. For example, the isolated peptide may be selected from the group consisting of KYGVLLKTL (SEQ ID NO:11); RYMRQFVAL (SEQ ID NO: 12); RYVSRLLGI (SEQ ID NO: 13); RYGKGWDLL (SEQ ID NO: 14); RYLVQVQAL (SEQ ID NO: 15); and RYWELSNHL (SEQ ID NO: 16).
1. An isolated peptide consisting of an immunogenic HLA-A*2402-restricted epitope, wherein said isolated peptide is selected from the group consisting of KYGVLLKTL (SEQ ID NO: 11); RYMRQFVAL (SEQ ID NO: 12); RYVSRLLGI (SEQ ID NO: 13); RYGKGWDLL (SEQ ID NO: 14); RYLVQVQAL (SEQ ID NO: 15); and RYWELSNHL (SEQ ID NO: 16).
2. A chimeric polypeptide, comprising one or more immunogenic HLA-A*2402-restricted epitopes according to claim 1 .
3. A kit of parts comprising, in separate containers:
(i) a first peptide with an amino acid sequence selected from the group consisting of PYGVLLKTH (SEQ ID NO: 1); PYMRQFVAH (SEQ ID NO: 2); PYVSRLLGI (SEQ ID NO: 3); PYGKGWDLM (SEQ ID NO: 4); TYLVQVQAL (SEQ ID NO: 5); PYWELSNHE (SEQ ID NO: 6); PYDGIPARE (SEQ ID NO: 7); RYEFLWGPR (SEQ ID NO: 8); and PYNYLSTDV (SEQ ID NO: 9); and
(ii) a second peptide comprising a sequence consisting of a HLA-A*2402-restricted immunogenic epitope,
wherein said second peptide is an immunogenic epitope, which has an amino acid sequence selected from the group consisting of KYGVLLKTL (SEQ ID NO: 11); RYMRQFVAL (SEQ ID NO: 12); RYVSRLLGI (SEQ ID NO: 13); RYGKGWDLL (SEQ ID NO: 14); RYLVQVQAL (SEQ ID NO: 15); and RYWELSNHL (SEQ ID NO: 16) and is derived from the first peptide by substituting its N-terminal residue with an arginine or a lysine, and/or by substituting its C-terminal residue with a leucine, an isoleucine, or a phenylalanine.
4. A kit of parts comprising, in separate containers:
(i) a first peptide comprising one or more HLA-A*2402-restricted cryptic epitopes that has an amino acid sequence selected from the group consisting of PYGVLLKTH (SEQ ID NO: 1); PYMRQFVAH (SEQ ID NO: 2); PYVSRLLGI (SEQ ID NO: 3); PYGKGWDLM (SEQ ID NO: 4); TYLVQVQAL (SEQ ID NO: 5); PYWELSNHE (SEQ ID NO: 6); PYDGIPARE (SEQ ID NO: 7); RYEFLWGPR (SEQ ID NO: 8) and PYNYLSTDV (SEQ ID NO: 9); and
(ii) a second peptide comprising one or more HLA-A*2402-restricted immunogenic epitopes derived from the HLA-A*2402-restricted cryptic epitopes,
wherein said second peptide is a chimeric polypeptide according to claim 2 , and wherein the at least one immunogenic epitope comprised in the second peptide is cognate to at least one HLA-A*2402-restricted cyptic epitope comprised in the first peptide.